menu
    • menu

    Company profile for Scancell

    NEW Drugs in Dev: 7
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Scancell's primary focus is to develop innovative immunotherapies for cancer that stimulate the body’s own immune system. A key challenge in the fight against cancer is that many tumours successfully evade the body’s own natural defences. Scancell’s mission is to overcome this by developing products that stimulate the immune system to treat or prevent cancer. The field of immuno-oncology is now established as a signific...
    Scancell's primary focus is to develop innovative immunotherapies for cancer that stimulate the body’s own immune system. A key challenge in the fight against cancer is that many tumours successfully evade the body’s own natural defences. Scancell’s mission is to overcome this by developing products that stimulate the immune system to treat or prevent cancer. The field of immuno-oncology is now established as a significant weapon in the war against cancer, driven largely by the approval of immune checkpoint inhibitors. However, checkpoint inhibitors alone are not effective in most patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Scancellunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    John Eccles House, Robert Robinson Avenue, Oxford, Science Park, Oxford OX4 4G...
    Telephone
    Telephone
    +44 (0) 1865 338 069
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.scancell.co.uk/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Scancell Wins FDA Fast Track for iSCIB1+ in Advanced Melanoma
    Scancell Wins FDA Fast Track for iSCIB1+ in Advanced Melanoma

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282221/0/en/scancell-receives-fda-fast-track-designation-for-iscib1-in-advanced-melanoma-and-provides-data-update-from-its-scope-phase-2-study.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    Interim Results for the six months ended 31 October 2025
    Interim Results for the six months ended 31 October 2025

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3228196/0/en/Interim-Results-for-the-six-months-ended-31-October-2025.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    Scancell Receives FDA IND Clearance for Phase 3 Melanoma Trial
    Scancell Receives FDA IND Clearance for Phase 3 Melanoma Trial

    26 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/26/3225238/0/en/Scancell-announces-FDA-clearance-of-IND-application-for-global-Phase-3-trial-of-iSCIB1-in-advanced-melanoma.html

    GLOBENEWSWIRE
    26 Jan 2026
    Share Share
    Pharmajet Chosen For Advanced Melanoma DNA Immunotherapy
    Pharmajet Chosen For Advanced Melanoma DNA Immunotherapy

    09 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260109445482/en/PharmaJets-Needle-free-Injection-System-Selected-to-Administer-DNA-Immunotherapy-for-Advanced-Melanoma-in-Late-stage-Clinical-Development-following-Positive-Phase-2-Data

    BUSINESSWIRE
    09 Jan 2026
    Share Share
    Scancell's iSCIB1+ Improves PFS in Advanced Melanoma
    Scancell's iSCIB1+ Improves PFS in Advanced Melanoma

    09 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/09/3202069/0/en/Scancell-updated-Phase-2-data-shows-continued-improvement-in-progression-free-survival-with-iSCIB1-in-patients-with-first-line-advanced-melanoma.html

    GLOBENEWSWIRE
    09 Dec 2025
    Share Share
    Research Update
    Research Update

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183379/0/en/Research-Update.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search